-transparent.png){kind=logo}
One hundred sixteen patients with metastatic breast cancer who achieved complete remission with combination chemotherapy were analyzed to ascertain the factors that affect the duration of complete remission and the patterns of relapse. The median duration of complete remission was 17 months. Disease recurred in 81 patients (70%) at periods ranging from 3 to 44 months after achievement of complete remission. The duration of complete remission was inversely related to the bulk of metastatic tumor. Twenty-three patients treated with combined oophorectomy and chemotherapy experienced the longest remissions (median duration of 33 months); only eight (35%) of them have relapsed. Seventy-six percent of the relapses occurred in previously known sites of tumor involvement; most of the remainder involved the brain. The short duration of complete remissions and tendency to relapse in sites of initial involvement suggest that patients with metastatic breast cancer who achieved complete remission with combination chemotherapy still had substantial residual tumor. Consolidation treatments, using hormonal therapy and non-cross-resistant chemotherapy along with irradiation to initial sites of metastases, whould be investigated to ascertain their usefulness in prolonging the remissions.
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
April 1989,
Gan no rinsho. Japan journal of cancer clinics,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
March 1977,
Annals of internal medicine,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
May 1979,
Cancer research,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
June 1973,
Ugeskrift for laeger,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
January 2012,
Journal of drug delivery,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
October 1973,
California medicine,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
January 2004,
The oncologist,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
August 1986,
American journal of clinical oncology,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
June 1983,
Cancer,
S S Legha, and
A U Buzdar, and
T L Smith, and
G N Hortobagyi, and
K D Swenerton, and
G R Blumenschein, and
E A Gehan, and
G P Bodey, and
E J Freireich
December 1980,
Cancer,
